Mercuro G, Rossetti Z L, Tocco L, Rivano C A, Cherchi A, Gessa G L
Eur J Clin Pharmacol. 1985;27(6):671-5. doi: 10.1007/BF00547047.
The effect of a single oral dose of bromocriptine 2.5 mg was evaluated in 11 normotensive and 6 hypertensive volunteers. 150 min after drug administration, a significant decrease in plasma noradrenaline concentration from 202 to 124 pg/ml in normotensive and from 197 to 119 pg/ml in hypertensive patients was observed. Plasma 3,4-dihydroxyphenylacetic acid, a major metabolite of dopamine, fell from 1132 to 956 pg/ml in normal subjects and from 1242 to 807 pg/ml in hypertensives. No change in plasma adrenaline was found. At the same time, mean arterial pressure showed a significant decrease from 90 to 81 and from 132 to 111 mmHg in normotensive and hypertensive subjects, respectively. Bromocriptine also inhibited the increase in noradrenaline level that occurred when the subjects changed from the supine to the standing position. The inhibition was more evident in hypertensive subjects. It is suggested that the hypotensive effect of bromocriptine is mediated by the inhibition of noradrenaline release due to the stimulation of dopamine receptors on noradrenergic nerve terminals.
在11名血压正常的志愿者和6名高血压志愿者中评估了单次口服2.5毫克溴隐亭的效果。给药150分钟后，观察到血压正常者血浆去甲肾上腺素浓度从202皮克/毫升显著降至124皮克/毫升，高血压患者从197皮克/毫升降至119皮克/毫升。多巴胺的主要代谢产物血浆3,4 - 二羟基苯乙酸，在正常受试者中从1132皮克/毫升降至956皮克/毫升，在高血压患者中从1242皮克/毫升降至807皮克/毫升。未发现血浆肾上腺素有所变化。与此同时，血压正常者和高血压受试者的平均动脉压分别从90毫米汞柱显著降至81毫米汞柱以及从132毫米汞柱降至111毫米汞柱。溴隐亭还抑制了受试者从仰卧位变为站立位时去甲肾上腺素水平的升高。这种抑制在高血压受试者中更为明显。有人提出，溴隐亭的降压作用是通过刺激去甲肾上腺素能神经末梢上的多巴胺受体来抑制去甲肾上腺素释放而介导的。
